Publication: Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches
Issued Date
2016-12-01
Resource Type
ISSN
17474094
17474086
17474086
Other identifier(s)
2-s2.0-85000868665
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Hematology. Vol.9, No.12 (2016), 1129-1137
Suggested Citation
Orapan Sripichai, Suthat Fucharoen Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches. Expert Review of Hematology. Vol.9, No.12 (2016), 1129-1137. doi:10.1080/17474086.2016.1255142 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/40931
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches
Author(s)
Other Contributor(s)
Abstract
© 2016 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Stress erythropoiesis induces fetal hemoglobin (HbF) expression in β-thalassemias, however the level of expression is highly variable. The last decade has seen dramatic advances in our understanding of the molecular regulators of HbF production and the genetic factors associated with HbF levels, leading to the promise of new methods of the clinical induction of HbF. Areas covered: This article will review the heterogeneity and genetic modifiers of HbF and HbF induction therapy in β-thalassemia. Expert commentary: One promising curative β-thalassemia therapy is to induce HbF synthesis in β-thalassemic erythrocytes to therapeutic levels before clinical symptom occurs. Further understanding of HbF level variation and regulation is needed in order to predict the response from HbF-inducing approaches.